Skip to main content
NCBI home page
British Journal of Clinical Pharmacology logoLink to British Journal of Clinical Pharmacology
. 1987 Oct;24(4):425–434. doi: 10.1111/j.1365-2125.1987.tb03194.x

Dipyridamole: pharmacokinetics and effects on aspects of platelet function in man.

D Gregov 1, A Jenkins 1, E Duncan 1, D Siebert 1, S Rodgers 1, B Duncan 1, F Bochner 1, J Lloyd 1
PMCID: PMC1386303  PMID: 2825745

Abstract

1. The effect of dipyridamole on platelet function was measured in twelve normal subjects given 150 or 200 mg tablets as single and multiple doses, and in six subjects given single doses of 25, 50 and 100 mg and multiple doses of 50 mg 8 hourly. 2. Platelet aggregation was measured in response to ADP and collagen. In the subjects given 150/200 mg, the platelets were assayed for content of cyclic AMP and for formation of thromboxane after addition of collagen. The responses to ADP and collagen and the cyclic AMP content were assessed in both the presence and absence of added PGE1. The pharmacokinetics of dipyridamole were studied in all subjects. 3. One hour after 150/200 mg single doses of dipyridamole there was significant inhibition of platelet aggregation in response to both collagen and ADP. There was no detectable effect on aggregation at other time points or with lower doses of dipyridamole. The addition of PGE1 to platelets prior to testing did not enhance the effect of dipyridamole on platelet aggregation. 4. In multiple doses, dipyridamole (150/200 mg twice daily for 11 days) had no detectable effect on platelet aggregation. 5. Dipyridamole did not have any effect on platelet cyclic AMP content, whether or not PGE1 was added prior to assay. 6. Dipyridamole did not affect platelet thromboxane formation. 7. Plasma dipyridamole concentrations were maximal 1-2 h after ingestion, at the same time that inhibition of platelet aggregation was detected. The concentrations declined in a biexponential fashion, with a terminal half life of 24.1 +/- 1.9 h (mean +/- s.e. mean). In six of the 17 subjects, the mean steady state plasma concentration was less than 75% of the value predicted from the single dose data.

Full text

PDF
425

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Best L. C., McGuire M. B., Jones P. B., Holland T. K., Martin T. J., Preston F. E., Segal D. S., Russell R. G. Mode of action of dipyridamole on human platelets. Thromb Res. 1979;16(3-4):367–379. doi: 10.1016/0049-3848(79)90084-7. [DOI] [PubMed] [Google Scholar]
  2. Cazenave J. P., Packham M. A., Mustard J. F. Adherence of platelets to a collagen-coated surface: development of a quantitative method. J Lab Clin Med. 1973 Dec;82(6):978–990. [PubMed] [Google Scholar]
  3. Cucuianu M. P., Nishizawa E. E., Mustard J. F. Effect of pyrimido-pyrimidine compounds on platelet function. J Lab Clin Med. 1971 Jun;77(6):958–974. [PubMed] [Google Scholar]
  4. Dresse A., Chevolet C., Delapierre D., Masset H., Weisenberger H., Bozler G., Heinzel G. Pharmacokinetics of oral dipyridamole (Persantine) and its effect on platelet adenosine uptake in man. Eur J Clin Pharmacol. 1982;23(3):229–234. doi: 10.1007/BF00547559. [DOI] [PubMed] [Google Scholar]
  5. Emmons P. R., Harrison M. J., Honour A. J., Mitchell J. R. Effect of dipyridamole on human platelet behaviour. Lancet. 1965 Sep 25;2(7413):603–606. doi: 10.1016/s0140-6736(65)90515-5. [DOI] [PubMed] [Google Scholar]
  6. FitzGerald G. A., Brash A. R., Falardeau P., Oates J. A. Estimated rate of prostacyclin secretion into the circulation of normal man. J Clin Invest. 1981 Nov;68(5):1272–1276. doi: 10.1172/JCI110373. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. FitzGerald G. A., Smith B., Pedersen A. K., Brash A. R. Increased prostacyclin biosynthesis in patients with severe atherosclerosis and platelet activation. N Engl J Med. 1984 Apr 26;310(17):1065–1068. doi: 10.1056/NEJM198404263101701. [DOI] [PubMed] [Google Scholar]
  8. Gray G. R., Wilson P. A., Douglas A. S. The effect on dipyridamole on platelet aggregation and adhesiveness. Scott Med J. 1968 Dec;13(12):409–415. doi: 10.1177/003693306801301202. [DOI] [PubMed] [Google Scholar]
  9. Gresele P., Zoja C., Deckmyn H., Arnout J., Vermylen J., Verstraete M. Dipyridamole inhibits platelet aggregation in whole blood. Thromb Haemost. 1983 Dec 30;50(4):852–856. [PubMed] [Google Scholar]
  10. Groves H. M., Kinlough-Rathbone R. L., Cazenave J. P., Dejana E., Richardson M., Mustard J. F. Effect of dipyridamole and prostacyclin on rabbit platelet adherence in vitro and in vivo. J Lab Clin Med. 1982 Apr;99(4):548–558. [PubMed] [Google Scholar]
  11. Harker L. A., Slichter S. J. Platelet and fibrinogen consumption in man. N Engl J Med. 1972 Nov 16;287(20):999–1005. doi: 10.1056/NEJM197211162872001. [DOI] [PubMed] [Google Scholar]
  12. Harker L. A., Slichter S. J. Studies of platelet and fibrinogen kinetics in patients with prosthetic heart valves. N Engl J Med. 1970 Dec 10;283(24):1302–1305. doi: 10.1056/NEJM197012102832402. [DOI] [PubMed] [Google Scholar]
  13. Jackson C. A., Greaves M., Preston F. E. A study of the stimulation of human venous prostacyclin synthesis by dipyridamole. Thromb Res. 1982 Sep 1;27(5):563–573. doi: 10.1016/0049-3848(82)90303-6. [DOI] [PubMed] [Google Scholar]
  14. Levine S. P., Suarez A. J., Sorenson R. R., Knieriem L. K., Raymond N. M. The importance of blood collection methods for assessment of platelet activation. Thromb Res. 1981 Dec 1;24(5-6):433–443. doi: 10.1016/0049-3848(81)90077-3. [DOI] [PubMed] [Google Scholar]
  15. Mahony C., Wolfram K. M., Cocchetto D. M., Bjornsson T. D. Dipyridamol kinetics. Clin Pharmacol Ther. 1982 Mar;31(3):330–338. doi: 10.1038/clpt.1982.42. [DOI] [PubMed] [Google Scholar]
  16. Mehta J., Mehta P., Hay D. Effect of dipyridamole on prostaglandin generation by human platelets and vessel walls. Prostaglandins. 1982 Dec;24(6):751–761. doi: 10.1016/0090-6980(82)90056-9. [DOI] [PubMed] [Google Scholar]
  17. Mehta J., Mehta P., Pepine C. J., Conti C. R. Platelet function studies in coronary artery disease. X. Effect of dipyridamole. Am J Cardiol. 1981 May;47(5):1111–1114. doi: 10.1016/0002-9149(81)90221-6. [DOI] [PubMed] [Google Scholar]
  18. Mills D. C., Smith J. B. The influence on platelet aggregation of drugs that affect the accumulation of adenosine 3':5'-cyclic monophosphate in platelets. Biochem J. 1971 Jan;121(2):185–196. doi: 10.1042/bj1210185. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Moncada S., Korbut R. Dipyridamole and other phosphodiesterase inhibitors act as antithrombotic agents by potentiating endogenous prostacyclin. Lancet. 1978 Jun 17;1(8077):1286–1289. doi: 10.1016/s0140-6736(78)91269-2. [DOI] [PubMed] [Google Scholar]
  20. Nielsen-Kudsk F., Pedersen A. K. Pharmacokinetics of dipyridamole. Acta Pharmacol Toxicol (Copenh) 1979 May;44(5):391–399. doi: 10.1111/j.1600-0773.1979.tb02350.x. [DOI] [PubMed] [Google Scholar]
  21. Nitelius E., Melander A., Wåhlin-Boll E. Pharmacokinetic interaction of acetylsalicylic acid and dipyridamole. Br J Clin Pharmacol. 1985 Mar;19(3):379–383. doi: 10.1111/j.1365-2125.1985.tb02657.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Rajah S. M., Crow M. J., Penny A. F., Ahmad R., Watson D. A. The effect of dipyridamole on platelet function: correlation with blood levels in man. Br J Clin Pharmacol. 1977 Apr;4(2):129–133. doi: 10.1111/j.1365-2125.1977.tb00683.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Rajah S. M., Penny A. F., Crow M. J., Pepper M. D., Watson D. A. The interaction of varying doses of dipyridamole and acetyl salicylic acid on the inhibition of platelet functions and their effect on bleeding time. Br J Clin Pharmacol. 1979 Nov;8(5):483–489. doi: 10.1111/j.1365-2125.1979.tb01031.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Rosenfeld J., Buchanan M. R., Reilly P. A., Turpie A. G. Dipyridamole disposition after chronic administration: effect of aspirin. Thromb Res Suppl. 1983;4:137–143. doi: 10.1016/0049-3848(83)90369-9. [DOI] [PubMed] [Google Scholar]
  25. Siebert D. J., Bochner F., Imhoff D. M., Watts S., Lloyd J. V., Field J., Gabb B. W. Aspirin kinetics and platelet aggregation in man. Clin Pharmacol Ther. 1983 Mar;33(3):367–374. doi: 10.1038/clpt.1983.47. [DOI] [PubMed] [Google Scholar]
  26. Steele P., Rainwater J., Vogel R. Effect of platelet suppressant treatment with dipyridamole and aspirin on exercise performance and platelet survival time in coronary disease. Chest. 1981 Nov;80(5):557–561. doi: 10.1378/chest.80.5.557. [DOI] [PubMed] [Google Scholar]
  27. Sullivan J. M., Harken D. E., Gorlin R. Pharmacologic control of thromboembolic complications of cardiac-valve replacement. A preliminary report. N Engl J Med. 1968 Sep 12;279(11):576–580. doi: 10.1056/NEJM196809122791104. [DOI] [PubMed] [Google Scholar]
  28. Sullivan J. M., Harken D. E., Gorlin R. Pharmacologic control of thromboembolic complications of cardiac-valve replacement. N Engl J Med. 1971 Jun 24;284(25):1391–1394. doi: 10.1056/NEJM197106242842501. [DOI] [PubMed] [Google Scholar]
  29. Van de Velde V. J., Bult H., Weisenberger H., Herman A. G. Dipyridamole stimulates prostacyclin production in isolated rat aortic tissue. Arch Int Pharmacodyn Ther. 1982 Apr;256(2):327–328. [PubMed] [Google Scholar]
  30. Watts S. E., Tunbridge L. J., Duncan E. M., Lloyd J. V. Storage of platelets for tests of platelet function: comparison of two methods of pH control. Thromb Res. 1985 Jan 1;37(1):73–83. doi: 10.1016/0049-3848(85)90034-9. [DOI] [PubMed] [Google Scholar]
  31. Weiss H. J., Turitto V. T., Vicic W. J., Baumgartner H. R. Effect of aspirin and dipyridamole on the interaction of human platelets with sub-endothelium: studies using citrated and native blood. Thromb Haemost. 1981 Apr 30;45(2):136–141. [PubMed] [Google Scholar]
  32. Wolfram K. M., Bjornsson T. D. High-performance liquid chromatographic analysis of dipyridamole in plasma and whole blood. J Chromatogr. 1980 Jul 11;183(1):57–64. doi: 10.1016/s0378-4347(00)81398-5. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Clinical Pharmacology are provided here courtesy of British Pharmacological Society

RESOURCES